PHARVARIS N.V. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.21 USD | -0.60% |
|
+11.79% | -16.83% |
| 15/04 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| 12/04 | Pharvaris Files Mixed Shelf | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.18B 1.26B 105B |
|---|---|---|---|---|---|
| Net income 2024 * | -115M -123M -10.28B | Net income 2025 * | -136M -146M -12.16B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 282M 302M 25.18B | Net cash position 2025 * | 161M 173M 14.41B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9.51
x | P/E ratio 2025 * |
-9.06
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | -0.60% | ||
| 1 week | +11.79% | ||
| Current month | +0.95% | ||
| 1 month | +7.81% | ||
| 3 months | -23.73% | ||
| 6 months | +37.56% | ||
| Current year | -16.83% |
1 week
19.59
25.44
1 month
17.5725.44
Current year
17.5733.00
1 year
7.9333.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 30/15/30 |
| Founder | 65 | 30/15/30 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | 15/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 30/15/30 | |
David Meeker
CHM | Chairman | 69 | 01/21/01 |
Robert Glassman
BRD | Director/Board Member | 62 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 23.33 | -0.09% | 27 361 |
| 26/24/26 | 23.35 | +2.55% | 85,067 |
| 25/24/25 | 22.77 | +7.15% | 82,367 |
| 24/24/24 | 21.25 | -0.19% | 34,153 |
| 23/24/23 | 21.29 | +2.01% | 88,778 |
Delayed Quote Nasdaq, April 29, 2024 at 08:54 pm IST
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
21.87
EUR
Average target price
31.03
EUR
Spread / Average Target
+41.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.83% | 1.26B | |
| +2.16% | 42.75B | |
| +47.64% | 41.61B | |
| +12.32% | 41.34B | |
| -12.36% | 26.59B | |
| +8.29% | 25.49B | |
| -23.19% | 18.12B | |
| +30.25% | 12.24B | |
| -1.37% | 11.76B | |
| +8.40% | 11B |
- Stock Market
- Equities
- PHVS Stock
